Alongside plans to spin out a new company, the Belgian drugmaker said it will cut some 300 positions, or about 40% of its ...

The split-up of Galapagos is only the latest shake-up in the company in recent years. Other major events have included the ...

Belgian biotech Galapagos (NASDAQ:GLPG) announced a major restructuring drive on Wednesday, with plans to amend its 10-year ...

Galapagos will gain full development and commercialization rights to its pipeline, and is subject to single digit royalty ...

By mid-2025, the biotech will split into two entities: a new, as-yet-unnamed innovative medicines specialist and a cell ...

The beleaguered Belgian firm Galapagos is splitting itself into two companies, with the brandname biotech prioritizing ...

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell ...

the Royalty Agreement, under which Galapagos will gain full global development and commercialization rights to its pipeline, subject to payment of single digit royalties to Gilead on net sales of ...

Galapagos (GLPG) announced a planned separation into two entities: a newly to be formed company, which would focus on building a pipeline of ...

As part of the restructuring, Galapagos and Gilead agreed to amend a major licensing and development deal they struck in 2019. Gilead will own about 25% of each of the two companies going forward ...